TY - JOUR
T1 - Evidence that oocyte maturation induced by an oncogenic ras-p21 protein and insulin is mediated by overlapping yet distinct mechanisms
AU - Chung, Denise L.
AU - Joran, Alvin
AU - Friedman, Fred
AU - Robinson, Richard
AU - Brandt-Rauf, Paul W.
AU - Weinstein, I. Bernard
AU - Ronai, Zeev
AU - Baskin, Leonard
AU - Dykes, Daryll C.
AU - Murphy, Randall B.
AU - Nishimura, Susumu
AU - Yamaizumi, Z.
AU - Pincus, Matthew R.
N1 - Funding Information:
This work was supported in part by NC1 Grant CA 42500 to M.R.P. and by NC1 Grant CA 02111, Program Project Grant CA2111-15, and an award from the National Foundation for Cancer Research to I.B.W. We thank Drs. Kevin O’Driscoll, Christof Borner, and Max Gottesman for many helpful discussions and suggestions. We also thank Dr. Thomas Meyer of CIBA-Geigy Ltd. (Basel, Switzerland) for the gifts of CGP 41 251 and other staurosporine derivatives and for very helpful discussions.
PY - 1992/12
Y1 - 1992/12
N2 - We have recently shown that a peptide (residues 35-47) from a functional region of the ras p21 protein, thought to be involved in the binding of p21 to GTPase activating protein, the antibiotic azatyrosine, known to induce the ras-recision gene, and the selective protein kinase C inhibitor, CGP 41 251, all inhibit oncogenic p21 protein-induced maturation of oocytes in a dose-dependent manner. We now show that these three agents only partially inhibit insulin-induced oocyte maturation, known to be dependent on activation of cellular p21 protein. On the other hand, the anti-p21 protein antibody Y13-259 completely inhibits both insulin- and oncogenic p21 protein-induced maturation as does a tetrapeptide, CVIM, known to block the enzyme farnesyl transferase which covalently attaches the farnesyl moiety to the p21 protein allowing it to attach to the cell membrane. Our results suggest that while the oncogenic and insulin-activated normal p21 proteins share certain elements of their signal transduction pathways in common, these pathways diverge and allow for selective inhibition of the oncogenic pathway.
AB - We have recently shown that a peptide (residues 35-47) from a functional region of the ras p21 protein, thought to be involved in the binding of p21 to GTPase activating protein, the antibiotic azatyrosine, known to induce the ras-recision gene, and the selective protein kinase C inhibitor, CGP 41 251, all inhibit oncogenic p21 protein-induced maturation of oocytes in a dose-dependent manner. We now show that these three agents only partially inhibit insulin-induced oocyte maturation, known to be dependent on activation of cellular p21 protein. On the other hand, the anti-p21 protein antibody Y13-259 completely inhibits both insulin- and oncogenic p21 protein-induced maturation as does a tetrapeptide, CVIM, known to block the enzyme farnesyl transferase which covalently attaches the farnesyl moiety to the p21 protein allowing it to attach to the cell membrane. Our results suggest that while the oncogenic and insulin-activated normal p21 proteins share certain elements of their signal transduction pathways in common, these pathways diverge and allow for selective inhibition of the oncogenic pathway.
UR - https://www.scopus.com/pages/publications/13644255338
U2 - 10.1016/0014-4827(92)90006-T
DO - 10.1016/0014-4827(92)90006-T
M3 - Article
C2 - 1459198
AN - SCOPUS:13644255338
SN - 0014-4827
VL - 203
SP - 329
EP - 335
JO - Experimental Cell Research
JF - Experimental Cell Research
IS - 2
ER -